A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors

Maud Toulmonde, et al. ESMO 2017, September 11, 2017, 13:15 [...]

Par |2019-07-02T09:19:25+02:00septembre 7th, 2017|Pexa-Vec, Publication|Commentaires fermés sur A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors
Lire la suite

TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells.

Roland Kratzer, et al. AASLD & Hepatology, October 2016 - [...]

Par |2019-07-02T12:00:45+02:00novembre 14th, 2016|Publication, TG1050|Commentaires fermés sur TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells.
Lire la suite

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition

Patricia Kleinpeter, et al. OncoImmunology, October 2016 – Download the [...]

Par |2019-07-02T12:07:22+02:00octobre 28th, 2016|Invir.IO, Publication|Commentaires fermés sur Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition
Lire la suite
Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166 67405 Illkirch Graffenstaden Cedex - France | Tel. : + 33 (0) 3 88 27 91 00 - Fax. : + 33 (0) 3 88 27 91 11
© 2019 Transgene - All rights reserved
Mentions légales - Crédits
Aller en haut